Alkermes plc
NASDAQ:ALKSBiotechnology
+$0.79 today
- Market cap
- $7.87B
- Beta
- 0.33
- P/E (TTM)
- 49.1
- EPS (TTM)
- $0.92
Volume 1.39M
Average 2.33M
ALKS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Alkermes plcNASDAQ: ALKS
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income declines year over year
Q3 FY2026 net income of $16.29M fell 80.3% year over year, ahead of the -100.1% change in trailing-twelve-month net income. Sequentially, it rose 3150.9% from the prior quarter.
Context
- Net income amounted to 16.4% of revenue in FY2025, down 7.2 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 14 analysts of -$77.58M (-132.1%) for the fiscal year ending Dec 2026, a slowdown from the -34.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $16.29M+3150.9% QoQ
- Last fiscal yearDec 2025
- $241.66M-34.2% YoY
- LTMSep 2026
- -$351K-100.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -80.3% | -176.2% | -95.9 pp |
| 1 year | -34.2% | -132.1% | -97.9 pp |
| 3-year CAGR | — | +22.2% | — |
| 5-year CAGR | +15.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 241.66M USD
- Year-over-year change
- -34.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 241.66M | -34.2% |
| FY2024 | 2024-12-31 | 367.07M | +3.2% |
| FY2023 | 2023-12-31 | 355.76M | +324.8% |
| FY2022 | 2022-12-31 | (158.27M) | -228.6% |
| FY2021 | 2021-12-31 | (48.17M) | — |
Net Income vs competitors
How ALKS compares with its peers on the latest reported figures
- ALKS's LTM Sep 2026 net income of $351K is the smallest of the 7 companies compared; the peer median is $167.99M.
- Its year-over-year change of -100.1% is the 6th highest of 7, against a peer median of +68.5%.
- Net income amounts to 0.0% of revenue for ALKS, versus a peer median of 21.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $901.05M | +144.5% | +16.7% | 19.1% | |
| LTM Sep 2026 | $702.5M | +64.1% | +45.8% | 19.0% | |
| LTM Jun 2026 | $384.12M | +72.9% | — | 33.7% | |
| LTM Mar 2026 | $239.55M | +441.4% | — | 110.0% | |
| LTM Jun 2026 | $191.64M | -22.4% | -0.7% | 24.7% | |
| LTM Jun 2026 | $144.33M | -323.8% | — | 17.4% | |
| LTM Sep 2026 | $351K | -100.1% | — | 0.0% | |
| Peer median (excluding ALKS) | $167.99M | +68.5% | +16.7% | 21.9% | |
Competitors are the stored peer set for ALKS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (48.17M) | (158.27M) | 355.76M | 367.07M | 241.66M |
| Depreciation & Amortization | 78.65M | 77.86M | 74.93M | 28.53M | 27.17M |
| Deferred Income Tax | 5.08M | (32.8M) | (99.9M) | 40.52M | 28.77M |
| Stock-Based Compensation | 87.62M | 94.25M | 100.91M | 96.64M | 98.72M |
| Change in Working Capital | (25.55M) | 12.71M | (36.66M) | (98.15M) | 119.12M |
| Accounts Receivables | (38.01M) | 25.25M | (44.51M) | (56.34M) | 55.49M |
| Inventory | (24.77M) | (31.02M) | (2.71M) | 3.09M | (14.06M) |
| Accounts Payables | 43.31M | 15.53M | 23.01M | (57.97M) | 100.89M |
| Other Working Capital | (6.08M) | 2.95M | (12.45M) | 13.06M | (23.2M) |
| Other Non-Cash Items | 4.08M | 27.28M | 6.33M | 4.51M | 5.31M |
| Operating Cash Flow | 101.72M | 21.04M | 401.35M | 439.12M | 520.75M |
| Capital Expenditures | (29.02M) | (38.26M) | (48.05M) | (33.48M) | (40.42M) |
| Acquisitions (Net) | (713K) | 485K | 0 | 97.98M | 2.79M |
| Purchases of Investments | (340.42M) | (309.67M) | (254.47M) | (486.55M) | (364.37M) |
| Sales of Investments | 295.01M | 281.63M | 355.52M | 310.29M | 697.49M |
| Other Investing Activities | 8.94M | 1.27M | 354K | 461K | 0 |
| Investing Cash Flow | (66.2M) | (64.54M) | 53.36M | (111.31M) | 295.5M |
| Debt Repayment | 20.32M | (3M) | (3M) | (291.79M) | 0 |
| Common Stock Issued | 25.32M | 19.63M | 16.76M | 27.57M | 43.41M |
| Common Stock Repurchased | (16.57M) | (18.2M) | (28.47M) | (200.28M) | (31.03M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (275M) | (29.64M) | 0 |
| Financing Cash Flow | 29.07M | (1.57M) | (289.71M) | (494.14M) | 12.38M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 64.58M | (45.07M) | 165M | (166.32M) | 828.63M |
| Free Cash Flow | 72.7M | (17.21M) | 353.31M | 405.64M | 480.33M |
Alkermes plc
NASDAQ:ALKS
Intrinsic Alpha fair value
Locked
Current Price
$46.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.